Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?

Oral Oncol. 2022 Jan:124:105455. doi: 10.1016/j.oraloncology.2021.105455. Epub 2021 Jul 10.

Authors

Muhammad Shahid Iqbal¹, Josef Kovarik², Rahul Patil², Charles G Kelly²

Affiliations

¹ Department of Clinical Oncology, Northern Centre of Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK. Electronic address: Shahid.Iqbal@nhs.net.
² Department of Clinical Oncology, Northern Centre of Cancer Care, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK.

PMID: 34253464
DOI: 10.1016/j.oraloncology.2021.105455

No abstract available

Keywords: 5FU; Cetuximab; Head and neck cancer; Palliative chemotherapy; Platinum; Taxanes.

Publication types

Letter

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cetuximab
Drug Therapy, Combination
Fluorouracil / therapeutic use
Head and Neck Neoplasms* / drug therapy
Humans
Neoplasm Recurrence, Local / drug therapy
Taxoids* / therapeutic use

Substances

Taxoids
Cetuximab
Fluorouracil